Phoenix Bio

研究開発

研究開発

Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection

    Yamamoto, N. Sato, Y. Munakata, T. Kakuni, M. Tateno, C. Sanada, T. Hirata, Y. Murakami, S.  Tanaka, Y. Chayama, K. Hatakeyama, H. Hyodo, M. Harashima, H. Kohara, M.

    J Hepatol. 2015 Oct 23. pii: S0168-8278(15)00713-8. doi: 10.1016/j.jhep.2015.10.014.

    Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir andBMS-788329 combination therapy in human hepatocyte chimeric mice

      Uchida, T. Hiraga, N. mamura, M. Yoshimi, S. Kan, H. Miyaki, E. Tsuge, M. Abe, H. Hayes, C. N. Aikata, H. Ishida, Y. Tateno, C. Ellis, J. D. Chayama, K.

      Virus Res. 2015 Nov 10. pii: S0168-1702(15)30117-9. doi: 10.1016/j.virusres.2015.11.010.

      Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice

        Kan, H. Hiraga, N. Imamura, M. Hayes, C. N. Uchida, T. Miyaki, E. Tsuge, M. Abe, H. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

        Antivir Ther. 2015 Nov 12. doi: 10.3851/IMP3009.

        Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones

          Murakami, E. Tsuge, M. Hiraga,  N.Kan, H. Uchida, T. Masaki, K. Nakahara, T. Ono, A. Miki, D. Kawaoka, T. Abe, H.Imamura, M. Aikata, H. Ochi, H. Hayes, C. N. Akita, T. Tanaka, J. Chayama, K.

          J Infect. 2015 Oct 26. pii: S0163-4453(15)00339-4. doi: 10.1016/j.jinf.2015.09.038.

          Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice

            Tateno, C. Kawase, Y. Tobita, Y. Hamamura, S. Ohshita, H. Yokomichi, H. Sanada, H. Kakuni, M. Shiota, A. Kojima, Y. Ishida, Y. Shitara, H. Wada, N. A. Tateishi, H. Sudoh, M. Nagatsuka, S. Jishage, K. Kohara, M.

            PLoS One. 2015 Nov 4;10(11):e0142145. doi: 10.1371/journal.pone.0142145. eCollection 2015.

            Assessment of chimeric mice with humanized livers in new drug development: generation of pharmacokinetics, metabolism and toxicity data for selecting the final candidate compound

              Kamimura, H. Ito, S.

              Xenobiotica. 2015 Oct 7:1-13.

              Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans

                Nakada, N. Kawamura, A. Kamimura, H. Sato, K. Kazuki, Y. Kakuni, M. Ohbuchi, M. Kato, K. Tateno, C. Oshimura, M. Usui, T.

                Biopharm Drug Dispos. 2015 Sep 9. doi: 10.1002/bdd.1990.

                第63回日本ウイルス学会学術集会でのPXBマウス・PXB-cells関連研究発表のご案内

                2015年 11月22日(日)~24日(火)に福岡国際会議場(福岡市博多区)にて開催の第63回日本ウイルス学会学術集会にてPXBマウス・PXB-cells関連研究発表がありましたので、ご案内申し上げます。

                Lack of infectivity of HBV in feces from patients with chronic hepatitis B virus infection, and infection using chimeric mice

                  Komatsu, H. Inui, A. Murano, T. Tsunoda, T. Sogo, T. Fujisawa, T.

                  BMC Res Notes. 2015 Aug 20;8:366. doi: 10.1186/s13104-015-1337-z.

                  Characterization of novel entecavir resistance mutations

                    Hayashi, S. Murakami, S. Omagari, K. Matsui, T. Iio, E. Isogawa, M. Watanabe, T. Karino, Y. Tanaka, Y.

                    J Hepatol. 2015 Sep;63(3):546-53. doi: 10.1016/j.jhep.2015.03.020. Epub 2015 Mar 25.

                    Preclinical characterization andin vivoefficacy of GSK8853, a small molecule inhibitor of the Hepatitis C virus NS4B protein

                      Pouliot, Jeffrey J. Thomson, Michael Xie, Mi Horton, Joseph Johnson, John Krull, David Mathis, Amanda Morikawa, Yoshio Parks, Derek Peterson, Richard, Shimada, Takashi Thomas, Elizabeth Vamathevan, Jessica Van Horn, Stephanie Xiong, Zhiping Hamatake, Robert  Peat, Andrew J.

                      Antimicrob. Agents Chemother. doi:10.1128/AAC.00813-15

                      4′-modified nucleoside analogs: Potent inhibitors active against entecavir-resistant hepatitis B virus

                        Takamatsu, Y. Tanaka, Y. Kohgo, S. Murakami, S. Singh, K. Das, D. Venzon, D.  J. Amano, M. Kuwata,N. Aoki, M. Delino, N. S. Hayashi, S. Takahashi, S. Sukenaga, Y. Haraguchi, K. Sarafianos, S. G. Maeda, K. Mitsuya, H.

                        Journal: Hepatology. 2015 Jun 29. doi: 10.1002/hep.27962.

                        Efficient engraftmentof human iPS cell-derived hepatocyte-like cells in uPA/SCID mice by overexpression of FNK, a Bcl-xmutant gene

                          Nagamoto, Y. Takayama, K. Tashiro, K. Tateno, C. Sakurai, F. Tachibana, M. Kawabata, K. Ikeda, K. Tanaka, Y. Mizuguchi, H.
                          Cell Transplant. 2014 May 6.

                          Development of Murine Cyp3a Knockout Chimeric Mice with Humanized Liver

                            Kato, K. Ohbuchi, M. Hamamura, S. Ohshita, H. Kazuki, Y. Oshimura, M. Sato, K. Nakada, N. Kawamura, A. Usui, T. Kamimura, H. Tateno, C.

                            Drug Metab Dispos. 2015 Aug;43(8):1208-17.

                             

                            Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti-CD81 monoclonal antibody

                              Ji, C. Liu, Y. Pamulapati, C. Bohini, S. Fertig, G. Schraeml, M. Rubas, W. Brandt, M. Ries, S. Ma, H. Klumpp, K.

                              Hepatology. 2015 Apr;61(4):1136-44.

                              Identification and characterization of metabolites of ASP015K, a novel oral Janus kinase inhibitor, in rats, chimeric mice with humanized liver, and humans

                                Nakada, N. Oda, K.

                                Xenobiotica. 2015 Apr 14:1-9.

                                Monoclonal Antibodies against Extracellular Domains of Claudin-1 Block Hepatitis C Virus Infection in a Mouse Model

                                  Fukasawa, M. Nagase, S. Shirasago, Y. Iida, M. Yamashita, M. Endo, K. Yagi, K. Suzuki, T. Wakita, T. Hanada, K. Kuniyasu, H. Kondoh, M.

                                  J Virol. 2015 May 1;89(9):4866-79.

                                  Postexposure Prophylactic Effect of Hepatitis B Virus (HBV)-Active Antiretroviral Therapy against HBV Infection

                                    Watanabe, T. Hamada-Tsutsumi, S. Yokomaku, Y. Imamura, J. Sugiura, W. Tanaka, Y.

                                    Antimicrob Agents Chemother. 2015 Feb;59(2):1292-8.

                                    Discovering novel direct acting antiviral agents for HBV using in silico screening

                                      Murakami, Y. Hayakawa, M. Yano, Y. Tanahashi, T. Enomoto, M. Tamori, A. Kawada, N. Iwadate, M. Umeyama, H.

                                      Biochem Biophys Res Commun. 2015 Jan 2;456(1):20-8.

                                      Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice

                                        Ishida Y, Yamasaki C, Yanagi A, Yoshizane Y, Fujikawa K, Watashi K, Abe H, Wakita T, Hayes CN, Chayama K, Tateno C

                                        Am J Pathol. 2015 May;185(5):1275-85. doi: 10.1016/j.ajpath.2015.01.028. Epub 2015 Mar 17.